Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A

  • Authors:
    • M. Indrova
    • J. Bubenik
    • J. Simova
    • J. Bieblova
    • T. Jandlova
    • M. Smahel
    • V. Vonka
    • H. Glazman-Kusnierczyk
    • E. Pajtasz-Piasecka
    • C. Radzikowski
    • R. Mikyskova
  • View Affiliations

  • Published online on: November 1, 2001     https://doi.org/10.3892/or.8.6.1371
  • Pages: 1371-1374
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The effectiveness of combined chemoimmunotherapy with ifosfamide derivative CBM-4A and granulocyte-macrophage colony-stimulating factor (GM-CSF) was investigated in two experimental tumor models, 3MC-induced MHC class I+ sarcoma Mc12 and HPV16 E6/E7 oncogene-induced MHC class I- carcinoma MK16, transplanted in syngeneic mice. Treatment of Mc12 and MK16 tumor-bearing mice with GM-CSF or CBM-4A alone produced moderate anti-tumor effects. However, when the tumor-bearing mice were first treated i.p. with a single dose of CBM-4A (150 mg/kg) and three days later peritumorally with five daily doses of GM-CSF (100 ng/day), substantially stronger tumor-inhibitory effects were observed. The results indicate that in both, MHC class I+ and MHC class I- tumors, the combined chemoimmunotherapy can inhibit tumor progression more effectively than GM-CSF therapy or chemotherapy alone, and they suggest that GM-CSF should be considered as adjuvant to chemotherapy in clinical trials with HPV 16-associated neoplasms.

Related Articles

Journal Cover

November-December 2001
Volume 8 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Indrova M, Bubenik J, Simova J, Bieblova J, Jandlova T, Smahel M, Vonka V, Glazman-Kusnierczyk H, Pajtasz-Piasecka E, Radzikowski C, Radzikowski C, et al: Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncol Rep 8: 1371-1374, 2001
APA
Indrova, M., Bubenik, J., Simova, J., Bieblova, J., Jandlova, T., Smahel, M. ... Mikyskova, R. (2001). Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncology Reports, 8, 1371-1374. https://doi.org/10.3892/or.8.6.1371
MLA
Indrova, M., Bubenik, J., Simova, J., Bieblova, J., Jandlova, T., Smahel, M., Vonka, V., Glazman-Kusnierczyk, H., Pajtasz-Piasecka, E., Radzikowski, C., Mikyskova, R."Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A". Oncology Reports 8.6 (2001): 1371-1374.
Chicago
Indrova, M., Bubenik, J., Simova, J., Bieblova, J., Jandlova, T., Smahel, M., Vonka, V., Glazman-Kusnierczyk, H., Pajtasz-Piasecka, E., Radzikowski, C., Mikyskova, R."Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A". Oncology Reports 8, no. 6 (2001): 1371-1374. https://doi.org/10.3892/or.8.6.1371